Personalized therapy in endometrial cancer: Challenges and opportunities

Prospective evaluation of insulin resistance among endometrial cancer patients

(2011) Jennifer K. Burzawa et al.   AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY

Cancer statistics, 2011

(2011) Rebecca Siegel et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Molecular clustering of endometrial carcinoma based on estrogen-induced gene expression

(2011) Shannon N. Westin et al.   CANCER BIOLOGY & THERAPY

Overcoming resistance: Targeting the PI3K/mTOR pathway in endocrine refractory breast cancer

(2011) Alison J. Butt   CANCER BIOLOGY & THERAPY

PIK3R1 (p85 ) Is Somatically Mutated at High Frequency in Primary Endometrial Cancer

(2011) M. E. Urick et al.   CANCER RESEARCH

Synthetic lethality of PARP inhibition in cancers lackingBRCA1andBRCA2mutations

(2011) Konstantin J. Dedes et al.   CELL CYCLE

Molecular Characteristics Predict Clinical Outcomes: Prospective Trial Correlating Response to the EGFR Tyrosine Kinase Inhibitor Gefitinib with the Presence of Sensitizing Mutations in the Tyrosine Binding Domain of the EGFR Gene

(2011) N. A. Rizvi et al.   CLINICAL CANCER RESEARCH

Fibroblast Growth Factor Receptors Are Components of Autocrine Signaling Networks in Head and Neck Squamous Cell Carcinoma Cells

(2011) M. E. Marshall et al.   CLINICAL CANCER RESEARCH

Present and Future of PI3K Pathway Inhibition in Cancer: Perspectives and Limitations

(2011) E. Ciraolo et al.   CURRENT MEDICINAL CHEMISTRY

Novel mitogen-activated protein kinase kinase inhibitors

(2011) Mark S Chapman et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Integrating biomarkers in clinical trials

(2011) Marc Buyse et al.   EXPERT REVIEW OF MOLECULAR DIAGNOSTICS

The landscape ofEGFRpathways and personalized management of non-small-cell lung cancer

(2011) Liang Cheng et al.   Future Oncology

Insulin-like growth factor-I receptor inhibition by specific tyrosine kinase inhibitor NVP-AEW541 in endometrioid and serous papillary endometrial cancer cell lines

(2011) Zohar Attias-Geva et al.   GYNECOLOGIC ONCOLOGY

Metformin Reverses Progestin Resistance in Endometrial Cancer Cells by Downregulating GloI Expression

(2011) Zhenbo Zhang et al.   INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER

Phase II Study of Temsirolimus in Women With Recurrent or Metastatic Endometrial Cancer: A Trial of the NCIC Clinical Trials Group

(2011) Amit M. Oza et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase II Trial of Bevacizumab in Recurrent or Persistent Endometrial Cancer: A Gynecologic Oncology Group Study

(2011) Carol Aghajanian et al.   JOURNAL OF CLINICAL ONCOLOGY

Assessing the Activity of Cediranib, a VEGFR-2/3 Tyrosine Kinase Inhibitor, against VEGFR-1 and Members of the Structurally Related PDGFR Family

(2011) S. R. Brave et al.   MOLECULAR CANCER THERAPEUTICS

PIK3CA Mutations in Patients with Advanced Cancers Treated with PI3K/AKT/mTOR Axis Inhibitors

(2011) F. Janku et al.   MOLECULAR CANCER THERAPEUTICS

Methodological and practical challenges for personalized cancer therapies

(2011) Ignacio I. Wistuba et al.   Nature Reviews Clinical Oncology

Screening for EGFR Mutations in Patients with Head and Neck Cancer Treated with Gefitinib on a Compassionate-Use Program: A Hellenic Cooperative Oncology Group Study

(2011) Samuel Murray et al.   Journal of Oncology

A phase 2 study of the oral mammalian target of rapamycin inhibitor, everolimus, in patients with recurrent endometrial carcinoma

(2010) Brian M. Slomovitz et al.   CANCER

Loss of Inhibitory Insulin Receptor Substrate-1 Phosphorylation Is an Early Event in Mammalian Target of Rapamycin-Dependent Endometrial Hyperplasia and Carcinoma

(2010) A. S. McCampbell et al.   Cancer Prevention Research

PTEN Loss Compromises Homologous Recombination Repair in Astrocytes: Implications for Glioblastoma Therapy with Temozolomide or Poly(ADP-Ribose) Polymerase Inhibitors

(2010) B. McEllin et al.   CANCER RESEARCH

Targeting Endocrine Resistance: Is There a Role for mTOR Inhibition?

(2010) Amna Sheri et al.   Clinical Breast Cancer

Biomarkers and Patient Selection for PI3K/Akt/mTOR Targeted Therapies: Current Status and Future Directions

(2010) John M.S. Bartlett   Clinical Breast Cancer

Crosstalk between Insulin/Insulin-like Growth Factor-1 Receptors and G Protein-Coupled Receptor Signaling Systems: A Novel Target for the Antidiabetic Drug Metformin in Pancreatic Cancer

(2010) E. Rozengurt et al.   CLINICAL CANCER RESEARCH

Dasatinib in solid tumors

(2010) Lori C Kim et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Akt inhibitors in clinical development for the treatment of cancer

(2010) Sumanta Kumar Pal et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Sunitinib for the management of advanced renal cell carcinoma

(2010) Bernard Escudier   Expert Review of Anticancer Therapy

Predictive and prognostic angiogenic markers in a gynecologic oncology group phase II trial of bevacizumab in recurrent and persistent ovarian or peritoneal cancer

(2010) Ernest S. Han et al.   GYNECOLOGIC ONCOLOGY

Deregulation of the PI3K and KRAS signaling pathways in human cancer cells determines their response to everolimus

(2010) Federica Di Nicolantonio et al.   JOURNAL OF CLINICAL INVESTIGATION

Phase 0 Clinical Trials in Oncology: An Exploratory Methodology for Constructing a Study With Patients Undergoing Surgery for Metastatic Disease

(2010) Marc Pocard et al.   JOURNAL OF CLINICAL ONCOLOGY

Immunohistochemical Methods for Predicting Cell of Origin and Survival in Patients With Diffuse Large B-Cell Lymphoma Treated With Rituximab

(2010) Paul N. Meyer et al.   JOURNAL OF CLINICAL ONCOLOGY

Metformin promotes progesterone receptor expression via inhibition of mammalian target of rapamycin (mTOR) in endometrial cancer cells

(2010) Ya Xie et al.   JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY

Molecular clustering based on ERα and EIG121 predicts survival in high-grade serous carcinoma of the ovary/peritoneum

(2010) Matthew P Schlumbrecht et al.   MODERN PATHOLOGY

Metformin in Cancer Therapy: A New Perspective for an Old Antidiabetic Drug?

(2010) I. Ben Sahra et al.   MOLECULAR CANCER THERAPEUTICS

PTEN Deficiency in Endometrioid Endometrial Adenocarcinomas Predicts Sensitivity to PARP Inhibitors

(2010) K. J. Dedes et al.   Science Translational Medicine

Somatic mutations are present in all members of the AKT family in endometrial carcinoma

(2009) A Dutt et al.   BRITISH JOURNAL OF CANCER

The oncogenic mutation in the pleckstrin homology domain of AKT1 in endometrial carcinomas

(2009) K Shoji et al.   BRITISH JOURNAL OF CANCER

Pharmacogenetics and pharmacogenomics of anticancer agents

(2009) R. S. Huang et al.   CA-A CANCER JOURNAL FOR CLINICIANS

EphA2 overexpression is associated with lack of hormone receptor expression and poor outcome in endometrial cancer

(2009) Aparna A. Kamat et al.   CANCER

Preclinical pharmacokinetics and in vitro metabolism of brivanib (BMS-540215), a potent VEGFR2 inhibitor and its alanine ester prodrug brivanib alaninate

(2009) Punit H. Marathe et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Targeting the RAF–MEK–ERK pathway in cancer therapy

(2009) Clara Montagut et al.   CANCER LETTERS

Impact of Epidermal Growth Factor Receptor and KRAS Mutations on Clinical Outcomes in Previously Untreated Non-Small Cell Lung Cancer Patients: Results of an Online Tumor Registry of Clinical Trials

(2009) D. M. Jackman et al.   CLINICAL CANCER RESEARCH

The Role of Fibroblast Growth Factors in Tumor Growth

(2009) M. Korc et al.   CURRENT CANCER DRUG TARGETS

Synthetic lethal targeting ofPTENmutant cells with PARP inhibitors

(2009) Ana M. Mendes-Pereira et al.   EMBO Molecular Medicine

Aflibercept (AVE0005): an alternative strategy for inhibiting tumour angiogenesis by vascular endothelial growth factors

(2009) Quincy Siu-Chung Chu   EXPERT OPINION ON BIOLOGICAL THERAPY

Cixutumumab

(2009) Kevin P McKian et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

FGFR2 as a molecular target in endometrial cancer

(2009) Sara A Byron et al.   Future Oncology

Molecular alterations of EGFR and PIK3CA in uterine serous carcinoma

(2009) Monica Prasad Hayes et al.   GYNECOLOGIC ONCOLOGY

AKT1 pleckstrin homology domain E17K activating mutation in endometrial carcinoma

(2009) Yoram Cohen et al.   GYNECOLOGIC ONCOLOGY

Phase II trial of trastuzumab in women with advanced or recurrent, HER2-positive endometrial carcinoma: A Gynecologic Oncology Group study

(2009) Gini F. Fleming et al.   GYNECOLOGIC ONCOLOGY

Metformin is a potent inhibitor of endometrial cancer cell proliferation—implications for a novel treatment strategy

(2009) Leigh A. Cantrell et al.   GYNECOLOGIC ONCOLOGY

Phase I, Pharmacokinetic, and Pharmacodynamic Study of AMG 479, a Fully Human Monoclonal Antibody to Insulin-Like Growth Factor Receptor 1

(2009) Anthony W. Tolcher et al.   JOURNAL OF CLINICAL ONCOLOGY

American Society of Clinical Oncology Provisional Clinical Opinion: Testing forKRASGene Mutations in Patients With Metastatic Colorectal Carcinoma to Predict Response to Anti–Epidermal Growth Factor Receptor Monoclonal Antibody Therapy

(2009) Carmen J. Allegra et al.   JOURNAL OF CLINICAL ONCOLOGY

Targeting the mTOR Signaling Network for Cancer Therapy

(2009) Funda Meric-Bernstam et al.   JOURNAL OF CLINICAL ONCOLOGY

Predictors of Competing Mortality in Advanced Head and Neck Cancer

(2009) Loren K. Mell et al.   JOURNAL OF CLINICAL ONCOLOGY

Molecular predictors of response to a humanized anti-insulin-like growth factor-I receptor monoclonal antibody in breast and colorectal cancer

(2009) J. Zha et al.   MOLECULAR CANCER THERAPEUTICS

Implications for KRAS status and EGFR-targeted therapies in metastatic CRC

(2009) Nicola Normanno et al.   Nature Reviews Clinical Oncology

Inhibition of Poly(ADP-Ribose) Polymerase in Tumors fromBRCAMutation Carriers

(2009) Peter C. Fong et al.   NEW ENGLAND JOURNAL OF MEDICINE

Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma

(2009) Tony S. Mok et al.   NEW ENGLAND JOURNAL OF MEDICINE

The Emerging Role of PARP Inhibitors in the Treatment of Epithelial Ovarian Cancer

(2009) Lilian T. Gien et al.   Journal of Oncology

Polymorphisms and Clinical Outcome in Recurrent Ovarian Cancer Treated with Cyclophosphamide and Bevacizumab

(2008) A. M. Schultheis et al.   CLINICAL CANCER RESEARCH

Mechanisms of Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer

(2008) J. A. Engelman et al.   CLINICAL CANCER RESEARCH

Advances in Targeting the Ras/Raf/MEK/Erk Mitogen-Activated Protein Kinase Cascade with MEK Inhibitors for Cancer Therapy

(2008) B. B. Friday et al.   CLINICAL CANCER RESEARCH

Lapatinib: A dual inhibitor of human epidermal growth factor receptor tyrosine kinases

(2008) P MEDINA et al.   CLINICAL THERAPEUTICS

Phase II Study of Erlotinib in Recurrent or Metastatic Endometrial Cancer: NCIC IND-148

(2008) Amit M. Oza et al.   JOURNAL OF CLINICAL ONCOLOGY

Cancer: The Road to Amiens

(2008) David J. Stewart et al.   JOURNAL OF CLINICAL ONCOLOGY

EGFR Antagonists in Cancer Treatment

(2008) Fortunato Ciardiello et al.   NEW ENGLAND JOURNAL OF MEDICINE

Drug-sensitive FGFR2 mutations in endometrial carcinoma

(2008) A. Dutt et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

An exploratory analysis of HER-2 amplification and overexpression in advanced endometrial carcinoma: A gynecologic oncology group study

(2007) T.A. Grushko et al.   GYNECOLOGIC ONCOLOGY